Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Kentaro Konishi, Tsuyoshi Minematsu, Yasuhisa Nagasaka & Kenji Tabata. (2019) Physiologically-based pharmacokinetic modeling for mirabegron: a multi-elimination pathway mediated by cytochrome P450 3A4, uridine 5'-diphosphate-glucuronosyltransferase 2B7, and butyrylcholinesterase. Xenobiotica 49:8, pages 912-921.
Read now
Read now
Danyi Lu, Dong Dong, Zhong Liu, Yifei Wang & Baojian Wu. (2015) Metabolism elucidation of BJ-B11 (a heat shock protein 90 inhibitor) by human liver microsomes: identification of main contributing enzymes. Expert Opinion on Drug Metabolism & Toxicology 11:7, pages 1029-1040.
Read now
Read now
Emilio Sacco, Riccardo Bientinesi, Daniele Tienforti, Marco Racioppi, Gaetano Gulino, Daniele D'Agostino, Matteo Vittori & Pierfrancesco Bassi. (2014) Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. Expert Opinion on Drug Discovery 9:4, pages 433-448.
Read now
Read now
Umberto Leone Roberti Maggiore, Linda Cardozo, Simone Ferrero, Filomena Sileo, Alice Cola, Marco Torella, Nicola Colacurci, Massimo Candiani & Stefano Salvatore. (2014)
Mirabegron in the treatment of overactive bladder. Expert Opinion on Pharmacotherapy 15:6, pages 873-887.
Read now
Read now
Karl-Erik Andersson. (2013) New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA. Therapeutics and Clinical Risk Management 9, pages 161-170.
Read now
Read now
Raymond T Lee, Mitchell Bamberger & Pamela Ellsworth. (2013) Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency. Research and Reports in Urology 5, pages 147-157.
Read now
Read now
Mahendra Kashyap & Pradeep Tyagi. (2013) The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option. Expert Opinion on Drug Metabolism & Toxicology 9:5, pages 617-627.
Read now
Read now
Articles from other publishers (36)
Patrick Masson, Zukhra Shaihutdinova & Oksana Lockridge. (2023) Drug and pro-drug substrates and pseudo-substrates of human butyrylcholinesterase. Biochemical Pharmacology 218, pages 115910.
Crossref
Crossref
Martin C. Michel, Linda Cardozo, Christopher J. Chermansky, Francisco Cruz, Yasuhiko Igawa, Kyu-Sung Lee, Arun Sahai, Alan J. Wein & Karl-Erik Andersson. (2023) Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders. Pharmacological Reviews 75:4, pages 554-674.
Crossref
Crossref
Karl-Erik Andersson, Helmut Madersbacher, Waleed Altaweel, Pawan Vasudeva & Yasuhiko Igawa. 2023. Handbook of Neurourology. Handbook of Neurourology
281
315
.
Karl-Erik Andersson, Helmut Madersbacher, Waleed Altaweel, Pawan Vasudeva & Yasuhiko Igawa. 2022. Handbook of Neurourology. Handbook of Neurourology
1
35
.
Shizuo Yamada, Junko Chimoto, Mizuki Shiho, Takashi Okura, Kana Morikawa, Hirokazu Wakuda & Kazumasa Shinozuka. (2021) Possible Involvement of Muscarinic Receptor Blockade in Mirabegron Therapy for Patients with Overactive Bladder. Journal of Pharmacology and Experimental Therapeutics 377:2, pages 201-206.
Crossref
Crossref
Pankaj Mandpe, Bala Prabhakar & Pravin Shende. (2020) Potential of Mirabegron and its Extended-release Formulations for the Treatment of Overactive Bladder Syndrome. Current Drug Metabolism 21:2, pages 79-88.
Crossref
Crossref
Jian Lin, Theunis C. Goosen, Susanna Tse, Hidetomi Yamagami & Bimal Malhotra. (2019) Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug‐Drug Interaction for Fesoterodine When Coadministered With Mirabegron. The Journal of Clinical Pharmacology 59:11, pages 1505-1518.
Crossref
Crossref
Kentaro Konishi, Tsuyoshi Minematsu, Yasuhisa Nagasaka & Kenji Tabata. (2019) Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment. Biopharmaceutics & Drug Disposition 40:5-6, pages 176-187.
Crossref
Crossref
John Meijer, Tom van den Berg, Robert Huls, Vincent Hofstede, Willem Niesing, Cas van den Beld & Walter Krauwinkel. (2019) Validation of LC–MS/MS methods for the determination of mirabegron and eight metabolites in human plasma in a paediatric population. Journal of Pharmaceutical and Biomedical Analysis 167, pages 155-160.
Crossref
Crossref
Lingdi Chen & Yu Zhang. (2019) Determination of Mirabegron in rat plasma by UPLC–MS/MS after oral and intravenous administration. Revista da Associação Médica Brasileira 65:2, pages 141-148.
Crossref
Crossref
Karl-Erik Andersson, Helmut Madersbacher, Waleed Altaweel, Pawan Vasudeva & Yasuhiko Igawa. 2019. Neurourology. Neurourology
231
259
.
Sophia Delpe Goodridge & Roger R. Dmochowski. 2019. Contemporary Pharmacotherapy of Overactive Bladder. Contemporary Pharmacotherapy of Overactive Bladder
115
131
.
Jeff A Engle & Christina Fair. (2017) Sirolimus and mirabegron interaction in a hematopoietic cell transplant patient. Journal of Oncology Pharmacy Practice 24:8, pages 627-631.
Crossref
Crossref
Nodi Dehvari, Edilson Dantas da Silva Junior, Tore Bengtsson & Dana Sabine Hutchinson. (2018) Mirabegron: potential off target effects and uses beyond the bladder. British Journal of Pharmacology 175:21, pages 4072-4082.
Crossref
Crossref
Kentaro Konishi, Daisuke Tenmizu & Shin Takusagawa. (2017) Identification of Uridine 5′-Diphosphate-Glucuronosyltransferases Responsible for the Glucuronidation of Mirabegron, a Potent and Selective β3-Adrenoceptor Agonist, in Human Liver Microsomes. European Journal of Drug Metabolism and Pharmacokinetics 43:3, pages 301-309.
Crossref
Crossref
S.D. Edmondson. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
714
737
.
Yuki Nomura, Hiromi Iitsuka, Junko Toyoshima, Kentaro Kuroishi, Toshifumi Hatta, Atsunori Kaibara, Masataka Katashima, Selina Moy & Taiji Sawamoto. (2016) Pharmacokinetic drug interaction study between overactive bladder drugs mirabegron and tolterodine in Japanese healthy postmenopausal females. Drug Metabolism and Pharmacokinetics 31:6, pages 411-416.
Crossref
Crossref
Martin C. Michel & Cees Korstanje. (2016) β3-Adrenoceptor agonists for overactive bladder syndrome: Role of translational pharmacology in a repositioning clinical drug development project. Pharmacology & Therapeutics 159, pages 66-82.
Crossref
Crossref
Xia Lv, Dan-Dan Wang, Lei Feng, Ping Wang, Li-Wei Zou, Da-Cheng Hao, Jie Hou, Jing-Nan Cui, Guang-Bo Ge & Ling Yang. (2016) A highly selective marker reaction for measuring the activity of human carboxylesterase 1 in complex biological samples. RSC Advances 6:6, pages 4302-4309.
Crossref
Crossref
Kyotaka Muta, Tatsuki Fukami & Miki Nakajima. (2015) A proposed mechanism for the adverse effects of acebutolol: CES2 and CYP2C19-mediated metabolism and antinuclear antibody production. Biochemical Pharmacology 98:4, pages 659-670.
Crossref
Crossref
Fan Zhou, Yuxia Zhou, Qiaogen Zou, Lili Sun & Ping Wei. (2015) Liquid Chromatographic Separation and Thermodynamic Investigation of Mirabegron Enantiomers on a Chiralpak AY-H Column. Journal of Chromatographic Science 53:8, pages 1361-1365.
Crossref
Crossref
Hiromi Iitsuka, Marcel van Gelderen, Masataka Katashima, Shin Takusagawa & Taiji Sawamoto. (2015) Pharmacokinetics of Mirabegron, a ?3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy East Asian Subjects. Clinical Therapeutics 37:5, pages 1031-1044.
Crossref
Crossref
Shingo Oda, Tatsuki Fukami, Tsuyoshi Yokoi & Miki Nakajima. (2015) A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development. Drug Metabolism and Pharmacokinetics 30:1, pages 30-51.
Crossref
Crossref
Marta Rossanese, Giacomo Novara, Ben Challacombe, Alessandro Iannetti, Prokar Dasgupta & Vincenzo Ficarra. (2015)
Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a ?
3
-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB)
. BJU International 115:1, pages 32-40.
Crossref
Crossref
Mai Shimizu, Tatsuki Fukami, Miki Nakajima & Tsuyoshi Yokoi. (2014) Screening of Specific Inhibitors for Human Carboxylesterases or Arylacetamide Deacetylase. Drug Metabolism and Disposition 42:7, pages 1103-1109.
Crossref
Crossref
Walter Krauwinkel, James Dickinson, Marloes Schaddelee, John Meijer, Reiner Tretter, Jeroen van de Wetering, Gregory Strabach & Marcel van Gelderen. (2013) The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. European Journal of Drug Metabolism and Pharmacokinetics 39:1, pages 43-52.
Crossref
Crossref
Hiromi Iitsuka, Tomoaki Tokuno, Yoko Amada, Hiroshi Matsushima, Masataka Katashima, Taiji Sawamoto, Shin Takusagawa, Marcel van Gelderen, Takanori Tanaka & Hideo Miyahara. (2013) Pharmacokinetics of Mirabegron, a ?3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy Japanese Male Subjects: Results from Single- and Multiple-Dose Studies. Clinical Drug Investigation 34:1, pages 27-35.
Crossref
Crossref
Karl-Erik Andersson. 2014. Bladder Dysfunction in the Adult. Bladder Dysfunction in the Adult
121
222
.
Christopher R. Chapple, Linda Cardozo, Victor W. Nitti, Emad Siddiqui & Martin C. Michel. (2014) Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability. Neurourology and Urodynamics 33:1, pages 17-30.
Crossref
Crossref
Karl-Erik Andersson, Nancy Martin & Victor Nitti. (2013)
Selective β
3
-Adrenoceptor Agonists for the Treatment of Overactive Bladder
. Journal of Urology 190:4, pages 1173-1180.
Crossref
Crossref
Karl-Erik Andersson. (2013) β3-Receptor Agonists for Overactive Bladder—New Frontier or More of the Same?. Current Urology Reports 14:5, pages 435-441.
Crossref
Crossref
Walter J. J. Krauwinkel, Virginie M. M. Kerbusch, John Meijer, Reiner Tretter, Gregory Strabach & E. Marcel Van Gelderen. (2013)
Evaluation of the Pharmacokinetic Interaction Between the β
3
-Adrenoceptor Agonist Mirabegron and the Muscarinic Receptor Antagonist Solifenacin In Healthy Subjects
. Clinical Pharmacology in Drug Development 2:3, pages 255-263.
Crossref
Crossref
Jennifer Lee, Selina Moy, John Meijer, Walter Krauwinkel, Taiji Sawamoto, Virginie Kerbusch, Donna Kowalski, Michael Roy, Alan Marion, Shin Takusagawa, Marcel van Gelderen & James Keirns. (2013) Role of Cytochrome P450 Isoenzymes 3A and 2D6 in the In Vivo Metabolism of Mirabegron, a β3-Adrenoceptor Agonist. Clinical Drug Investigation 33:6, pages 429-440.
Crossref
Crossref
Shin Takusagawa, Fumihiko Ushigome, Hiroyuki Nemoto, Yutaka Takahashi, Qun Li, Virginie Kerbusch, Aiji Miyashita, Takafumi Iwatsubo & Takashi Usui. (2013)
Intestinal Absorption Mechanism of Mirabegron, a Potent and Selective β
3
-Adrenoceptor Agonist: Involvement of Human Efflux and/or Influx Transport Systems
. Molecular Pharmaceutics 10:5, pages 1783-1794.
Crossref
Crossref
James Dickinson, Michaelene Lewand, Taiji Sawamoto, Walter Krauwinkel, Marloes Schaddelee, James Keirns, Virginie Kerbusch, Selina Moy, John Meijer, Donna Kowalski, Richard Morton, Kenneth Lasseter, Dennis Riff, Viera Kup?ov?Marcel van Gelderen. (2012) Effect of Renal or Hepatic Impairment on the Pharmacokinetics of Mirabegron. Clinical Drug Investigation 33:1, pages 11-23.
Crossref
Crossref
Walter Krauwinkel, Jan van Dijk, Marloes Schaddelee, Charlotte Eltink, John Meijer, Gr?gory Strabach, Sjoerd van Marle, Virginie Kerbusch & Marcel van Gelderen. (2012) Pharmacokinetic Properties of Mirabegron, a ?3-Adrenoceptor Agonist: Results From Two Phase I, Randomized, Multiple-Dose Studies in Healthy Young and Elderly Men and Women. Clinical Therapeutics 34:10, pages 2144-2160.
Crossref
Crossref